Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

Stock MarketsJan 25, 2019 03:43PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg

By Caroline Humer and Deena Beasley

NEW YORK (Reuters) - CVS Health Corp (NYSE:CVS), a top U.S. manager of pharmacy benefits, has added new migraine drugs from Teva Pharmaceutical Industries (NYSE:TEVA) and Eli Lilly (NYSE:LLY) and Co to its list of covered drugs, excluding a rival treatment from Amgen Inc (NASDAQ:AMGN), a CVS spokeswoman told Reuters on Friday.

CVS's decision represents a setback for sales of Amgen's Aimovig, as many patients who rely on the coverage list will now have easier access to the rival Teva and Lilly drugs. Inclusion on the preferred drugs lists by the largest pharmacy benefit managers (PBMs) and health insurers is seen as critically important for sales of new medicines.

About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData.

Shares of Amgen fell 1.3 percent to $198.27. Teva shares traded in New York were up 1.3 percent at $19.60, while Lilly was off 0.5 percent at $114.36.

An Amgen spokeswoman said the company was disappointed by the CVS decision and that it would work toward Aimovig being a preferred brand on CVS coverage lists.

The move by CVS is a positive development for Teva, whose drug was initially excluded from the list of covered drugs by Express Scripts (NASDAQ:ESRX), another large U.S. PBM. Its status recently changed and it may appear on some coverage lists, but likely with a higher out-of-pocket cost, Express Scripts said on Friday.

Teva's Ajovy and Lilly's Emgality will be available to members who have tried and failed to be helped by other preventive migraine treatments, CVS spokeswoman Christine Cramer said in an emailed statement.

The treatments belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines, and whose prices were backed as cost effective by the Institute for Clinical and Economic Review, Cramer said. ICER is a non-partisan research organization that reviews the clinical and economic value of medicines.

Cramer did not provide a reason for why the company had excluded Amgen.

PBMs typically extract discounts from drugmakers in return for favorable placement on their list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members.

A Teva spokeswoman said in a statement that 60 percent of commercial patients now have access to Ajovy through covered drug lists and that discussions are continuing with other national and regional payers.

All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect rebates and discounts drugmakers typically provide to PBMs, who design and negotiate benefits for employers and insurers.

All three companies have said that they are providing a limited duration supply of these drugs at no cost directly to patients in addition to other assistance programs.

Amgen was the first of the three companies to launch a drug in the new class. The rival drugs from Teva and Lilly, which work in a similar manner, came on the market soon after.

CVS' policy is similar to that of Express Scripts, which requires patients first try two older preventive therapies and a triptan, a family of generic drugs used to treat acute migraine. Express is now part of Cigna Corp (NYSE:CI).

Lilly did not respond to a request for comment.

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email